Germany

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after […]

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232 Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648

This is an early-phase clinical trial testing a new drug called BI-1607 for people with melanoma that has spread or cannot be removed by surgery. The aim is to see whether combining BI-1607 with two existing treatments, ipilimumab and pembrolizumab, is safe and more effective than current options. BI-1607 is designed to help the body’s

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648 Read More »

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881

This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881 Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690 Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332 Read More »

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma – NCT05907954

Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma – NCT05907954 Read More »